Kyle Fargen to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Kyle Fargen has written about Randomized Controlled Trials as Topic.
Connection Strength
0.413
-
Rai AT, Leslie-Mazwi TM, Fargen KM, Pandey AS, Dabus G, Hassan AE, Fraser JF, Hirsch JA, Gupta R, Hanel R, Yoo AJ, Bozorgchami H, Fiorella D, Mocco J, Arthur AS, Zaidat O, Siddiqui AH. Neuroendovascular clinical trials disruptions due to COVID-19. Potential future challenges and opportunities. J Neurointerv Surg. 2020 Sep; 12(9):831-835.
Score: 0.152
-
Fargen KM, Fiorella D, Albuquerque F, Mocco J. Systematic regionalization of stroke care. J Neurointerv Surg. 2015 Apr; 7(4):229-30.
Score: 0.105
-
Fargen KM, Neal D, Fiorella DJ, Turk AS, Froehler M, Mocco J. A meta-analysis of prospective randomized controlled trials evaluating endovascular therapies for acute ischemic stroke. J Neurointerv Surg. 2015 Feb; 7(2):84-9.
Score: 0.103
-
Mocco J, Fargen KM, Goyal M, Levy EI, Mitchell PJ, Campbell BC, Majoie CB, Dippel DW, Khatri P, Hill MD, Saver JL. Neurothrombectomy trial results: stroke systems, not just devices, make the difference. Int J Stroke. 2015 Oct; 10(7):990-3.
Score: 0.027
-
Mocco J, Fiorella D, Fargen KM, Albuquerque F, Chen M, Gupta R, Hirsch JA, Linfante I, Mack W, Rai AT, Tarr RW. Endovascular therapy for acute ischemic stroke is indicated and evidence based: a position statement. J Neurointerv Surg. 2015 Feb; 7(2):79-81.
Score: 0.026